'Sir John Charnley' Hip Surgery Unit, Institute of Orthopaedics 'Carlos E. Ottolenghi', Italian Hospital of Buenos Aires, Buenos Aires, Argentina.
J Arthroplasty. 2021 Dec;36(12):3938-3944. doi: 10.1016/j.arth.2021.08.020. Epub 2021 Aug 27.
The ideal dose of intravenous glucocorticoids to control pain in total hip arthroplasty (THA) remains unclear. This randomized controlled trial compared postoperative pain and tramadol requirement in patients undergoing unilateral primary THA who received one versus two perioperative doses of dexamethasone.
Patients consented to undergo blinded, simple randomization to either one (at anesthetic induction [1D-group]: 54 patients) or two (with an additional dose 8 hours after surgery [2D-group]: 61 patients) perioperative doses of 8-mg intravenous dexamethasone. Pain was evaluated with visual analog scale at 8, 16, and 24 hours postoperatively and with tramadol requirement. The secondary outcomes included postoperative nausea and vomiting, time to ambulation, and length of stay.
Age (mean, 66 ± 13 years), body mass index (mean, 29 ± 5), gender (60% female), and history of diabetes were similar between groups (P >.05). Pain was higher at 16 (4 [interquartile range {IQR} 3-5] vs 2 [IQR 1-3]; P <.001) and 24 (2.5 [IQR 2-3] vs 1 [IQR 0-1] P <.001) hours postoperatively in the 1D-group patients. 1D-group patients had significantly more tramadol consumption (50 [IQR 50-100] vs 0 [IQR 0-50]; P = .01), as well as postoperative nausea and vomiting (18 [33.3%] vs 5 [8.2%]; P = .001). Fifty-five (90%) patients in the 2D-group and 32 (59%) in the 1D-group ambulated on postoperative day 0 (P = .0002). Fifty-eight (95%) patients in the 2D-group and 37 (68%) in the 1D-group were discharged on postoperative day 1 (P = .0002).
An additional dose of dexamethasone at 8 hours postoperatively significantly reduced pain, tramadol consumption, time to ambulation, and length of stay after primary THA.
控制全髋关节置换术(THA)术后疼痛的理想静脉内糖皮质激素剂量仍不清楚。本随机对照试验比较了接受单侧初次 THA 的患者在接受单次与两次围手术期地塞米松治疗后术后疼痛和曲马多需求的差异。
患者同意接受盲法、简单随机分组,分别接受单次(麻醉诱导时[1D 组]:54 例)或两次(术后 8 小时追加 1 次[2D 组]:61 例)围手术期 8mg 静脉内地塞米松。术后 8、16 和 24 小时用视觉模拟评分法评估疼痛,并评估曲马多需求。次要结局包括术后恶心呕吐、下床活动时间和住院时间。
年龄(均值,66±13 岁)、体重指数(均值,29±5)、性别(60%女性)和糖尿病史在两组间相似(P>.05)。1D 组患者在术后 16(4[四分位间距 {IQR} 3-5] vs 2[IQR 1-3];P<.001)和 24 小时(2.5[IQR 2-3] vs 1[IQR 0-1];P<.001)时疼痛更高。1D 组患者曲马多消耗量显著更多(50[IQR 50-100] vs 0[IQR 0-50];P=.01),且术后恶心呕吐发生率更高(18[33.3%] vs 5[8.2%];P=.001)。2D 组 55(90%)例和 1D 组 32(59%)例患者在术后第 0 天开始行走(P=.0002)。2D 组 58(95%)例和 1D 组 37(68%)例患者在术后第 1 天出院(P=.0002)。
在初次 THA 术后 8 小时给予额外剂量地塞米松可显著减轻疼痛、曲马多消耗量、下床活动时间和住院时间。